Semaglutide vs Cagrilintide: What’s the Difference?
The main difference between Semaglutide and Cagrilintide is mechanism: Semaglutide is studied for weight loss and blood sugar research — GLP-1 receptor agonist. Cagrilintide is studied for satiety and amylin pathway research — Long-acting amylin analogue.
GLP-1 incretin vs long-acting amylin analog.
Key differences between Semaglutide and Cagrilintide
- •Mechanism: Semaglutide — GLP-1 receptor agonist. Cagrilintide — Long-acting amylin analogue.
- •Primary research focus: Semaglutide is studied for weight loss and blood sugar research; Cagrilintide is studied for satiety and amylin pathway research.
- •Depth of human research: Semaglutide — Strong; Cagrilintide — Moderate.
- •Typical study cadence cited in the literature: Semaglutide — Once weekly, subcutaneous (abdomen, thigh, or upper arm); Cagrilintide — Once weekly, subcutaneous.
| Attribute | Semaglutide GLP-1 receptor agonist | Cagrilintide Long-acting amylin analog |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | Weight loss and blood sugar research | Satiety and amylin pathway research |
| Mechanism of action | GLP-1 receptor agonist. Slows gastric emptying, suppresses appetite at hypothalamic level, improves insulin sensitivity. | Long-acting amylin analogue. Slows gastric emptying and contributes to satiety via different pathway than GLP-1s. |
| Human research | Strong | Moderate |
| Animal research | Strong | Moderate |
| Mechanistic research | Established | Established |
| Study cadence cited | Once weekly, subcutaneous (abdomen, thigh, or upper arm) | Once weekly, subcutaneous |
| In plain English | Semaglutide mimics the hormone your gut releases when you eat. The brain reads it as 'we're full,' appetite drops, and stomach emptying slows down. | Amylin is a hormone released with insulin that tells your brain you're full. Cagrilintide mimics it on a long schedule. |
| How it works | Activates the GLP-1 receptor in the pancreas, brain, and gut — increasing insulin secretion, slowing gastric emptying, and reducing appetite through hypothalamic signaling. | Activates amylin receptors, slowing gastric emptying and reducing food intake via the area postrema in the brain. |
| Researchers study | Glycemic control, weight reduction, cardiovascular outcomes, and emerging research in addiction and neuroinflammation. | Body weight reduction alone and combined with Semaglutide (CagriSema). |
| Internet discussion | The internet talks about Semaglutide constantly — 'Ozempic face,' food noise reduction, alcohol cravings dropping, and dose-titration questions. | Discussed as the secret to lifting GLP-1 weight loss plateaus. |
Mechanism and research evidence, side by side
How Semaglutide and Cagrilintide differ at the receptor level, and how much published research currently supports each. Evidence ratings describe the depth of publicly available literature — they are not claims of safety or effectiveness.
Semaglutide
GLP-1 receptor agonist. Slows gastric emptying, suppresses appetite at hypothalamic level, improves insulin sensitivity.
- Incretin and appetite-regulating receptors
- Slowed gastric emptying and altered satiety signalling
- Energy-balance and glycaemic research endpoints
- Human research
- Strong
- Animal research
- Strong
- Mechanistic research
- Established
Weight loss, Type 2 diabetes management, appetite suppression
Cagrilintide
Long-acting amylin analogue. Slows gastric emptying and contributes to satiety via different pathway than GLP-1s.
- Incretin and appetite-regulating receptors
- Slowed gastric emptying and altered satiety signalling
- Energy-balance and glycaemic research endpoints
- Human research
- Moderate
- Animal research
- Moderate
- Mechanistic research
- Established
Prevent weight loss plateau, enhance satiety beyond GLP-1 alone
Semaglutide
Weight loss and blood sugar research
Semaglutide mimics the hormone your gut releases when you eat. The brain reads it as 'we're full,' appetite drops, and stomach emptying slows down.
Activates the GLP-1 receptor in the pancreas, brain, and gut — increasing insulin secretion, slowing gastric emptying, and reducing appetite through hypothalamic signaling.
Glycemic control, weight reduction, cardiovascular outcomes, and emerging research in addiction and neuroinflammation.
The internet talks about Semaglutide constantly — 'Ozempic face,' food noise reduction, alcohol cravings dropping, and dose-titration questions.
Semaglutide is the reference GLP-1 agonist — well-studied for blood sugar control and significant weight reduction.
Cagrilintide
Satiety and amylin pathway research
Amylin is a hormone released with insulin that tells your brain you're full. Cagrilintide mimics it on a long schedule.
Activates amylin receptors, slowing gastric emptying and reducing food intake via the area postrema in the brain.
Body weight reduction alone and combined with Semaglutide (CagriSema).
Discussed as the secret to lifting GLP-1 weight loss plateaus.
Cagrilintide is a long-acting amylin analog studied as an add-on to GLP-1 agonists for additional satiety and weight loss.